

39. Tuberculosis drug resistance and susceptibility testing in a nutshell
Saturday, 05 December 2015, 12:30-13:30

Chair: Amy PIATEK (USA)

Track: Drug resistance determination - molecular and phenotypic

- PC-1025-05** **Determinants of pulmonary tuberculosis among women in Afghanistan**
Sd Mahmoodi, M Seddiq, Mr Aloudal, M Mashal, S Sardar Mohammad, Ghul Qader (*Afghanistan*)
- PC-1026-05** **Evaluation of the BACTEC MGIT 960 system for bedaquiline susceptibility testing of *Mycobacterium tuberculosis***
G Torrea, N Coeck, C Desmaretz, T Van De Parre, T Van Poucke, N Lounis, B C De Jong, L Rigouts (*Belgium*)
- PC-1027-05** **The potential impact of up-front drug susceptibility testing on India's MDR-TB epidemic**
Ks Sachdeva, N Raizada, A Sreenivas, C Denkinge, C Paramasivan, S Kulsange, C Boehme, N Arinaminpathy (*India, Switzerland, UK*)
- PC-1028-05** **Linezolid susceptibility of XDR-TB strains from Pakistan tested on the MGIT 960 system**
J Farooqi, K Jabeen, S Shafiq, R Hasan (*Pakistan*)
- PC-1029-05** **Comparison of the MDR/XDR-TB Colour Test, Xpert[®] MTB/RIF, and MODS assays to diagnose rifampicin-resistant TB**
M Tovar, E Ramos, T Valencia, S Datta, R Montoya, R Montoya, Tom Wingfield, A Valencia, R Patrocinio, C Evans (*Peru, UK*)
- PC-1030-05** **Exploring drug resistant tuberculosis profiles in the West Coast region of the Western Cape Province, South Africa**
P Tshavhungwe, R M Warren, M Buckley, T Dolby, P Van Helden, J Simpson, K Jacobson, E Streicher (*South Africa, USA*)
- PC-1031-05** **Direct comparison of spontaneously expectorated sputum with sputum expectorated following mouth wash with water or with chlorhexidine**
C Kleinhans, M Hanekom, S Friedrich, A Venter, A Diacon (*South Africa*)
- PC-1032-05** **Molecular testing for tuberculosis in the United States: implications for national surveillance**
L Armstrong, T Dalton, R Oatis, J Higashi, S Allen, M Pecha, A Starks (*USA*)